Biora Therapeutics
Developer of ingestible device platforms for targeted and systemic delivery of large-molecule therapeutics and for ingestible diagnostics. Core work includes design, preclinical testing and early clinical evaluation of smart capsules that (1) autonomously localize in the GI tract to deliver liquid drug payloads to the colon and (2) use a liquid-jet mechanism to inject biomolecules into the small intestine for systemic uptake. The company publishes PK/PD and device-function data, pursues GMP scale-up and regulatory filings, and maintains a patent portfolio.
Industries
Nr. of Employees
medium (51-250)
Biora Therapeutics
Patents
Products
Colon-targeted ingestible capsule for localized liquid drug delivery
An ingestible smart capsule that autonomously localizes to the colon and releases a liquid therapeutic payload to coat the colon or deliver drug to colonic tissue for treatment of inflammatory bowel disease.
Ingestible liquid-jet capsule for systemic delivery of biomolecules
A swallowable device that uses an enteric trigger and internal liquid-jet mechanism to inject liquid drug formulations into the small-intestinal wall to enable systemic uptake of proteins, peptides, antibodies and nucleic acids without needles.
Ingestible diagnostic capsule with onboard assay and real-time readout
A lab-in-a-capsule diagnostic device that samples intestinal fluid at a programmed site and performs an onboard assay with real-time data transmission for indications such as SIBO and site-specific microbiome sampling.
Drug-device combination development (oral formulations for targeted or systemic capsule delivery)
Development of oral liquid formulations combined with ingestible delivery devices to enable localized colon delivery (e.g., tofacitinib formulations) or systemic uptake (e.g., antibody or peptide formulations) via capsule platforms.
Colon-targeted ingestible capsule for localized liquid drug delivery
An ingestible smart capsule that autonomously localizes to the colon and releases a liquid therapeutic payload to coat the colon or deliver drug to colonic tissue for treatment of inflammatory bowel disease.
Ingestible liquid-jet capsule for systemic delivery of biomolecules
A swallowable device that uses an enteric trigger and internal liquid-jet mechanism to inject liquid drug formulations into the small-intestinal wall to enable systemic uptake of proteins, peptides, antibodies and nucleic acids without needles.
Ingestible diagnostic capsule with onboard assay and real-time readout
A lab-in-a-capsule diagnostic device that samples intestinal fluid at a programmed site and performs an onboard assay with real-time data transmission for indications such as SIBO and site-specific microbiome sampling.
Drug-device combination development (oral formulations for targeted or systemic capsule delivery)
Development of oral liquid formulations combined with ingestible delivery devices to enable localized colon delivery (e.g., tofacitinib formulations) or systemic uptake (e.g., antibody or peptide formulations) via capsule platforms.
Expertise Areas
- Ingestible device development for drug delivery
- Targeted gastrointestinal delivery
- Systemic oral delivery of large molecules
- Preclinical large-animal pharmacology and PK/PD
Key Technologies
- Ingestible electronic capsule platforms
- Liquid-jet injection for intestinal delivery
- Autonomous anatomical localization sensors
- Enteric-triggered release systems
News & Updates
Announcement of planned first-in-human clinical trial to evaluate an ingestible liquid-jet capsule for oral, needle-free administration of a monoclonal antibody with topline data expected in early 2027.
Progress update reporting >25% mean oral bioavailability versus IV in swine and non-human primates for peptides and antibodies and over 600 devices dosed in large-animal studies with no safety-related issues identified in the preclinical program.
Completion of court-supervised restructuring; company emerged as a privately held entity with new financing to support development and GMP scaling of the oral liquid-jet platform.
Recognition in an industry report analyzing smart delivery formulations for biologics, highlighting the promise of the ingestible liquid-jet delivery capsule.
Topline results from a Phase 1 clinical trial of a colon-targeted liquid formulation of tofacitinib showed drug absorption in colonic tissue with lower peak systemic exposure versus conventional oral delivery.
Announcement of planned first-in-human clinical trial to evaluate an ingestible liquid-jet capsule for oral, needle-free administration of a monoclonal antibody with topline data expected in early 2027.
Progress update reporting >25% mean oral bioavailability versus IV in swine and non-human primates for peptides and antibodies and over 600 devices dosed in large-animal studies with no safety-related issues identified in the preclinical program.
Completion of court-supervised restructuring; company emerged as a privately held entity with new financing to support development and GMP scaling of the oral liquid-jet platform.
Recognition in an industry report analyzing smart delivery formulations for biologics, highlighting the promise of the ingestible liquid-jet delivery capsule.
Topline results from a Phase 1 clinical trial of a colon-targeted liquid formulation of tofacitinib showed drug absorption in colonic tissue with lower peak systemic exposure versus conventional oral delivery.